Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib trial of oral azacitidine in combination with lenalidomide and dexamethasone (Rd) for myeloma patients with relapsed and/or refractory multiple myeloma who have failed a prior lenalidomide-containing regimen
Other Non-Commercial Sponsor
This study will investigate the safety and tolerabilty of escalating doses of oral azacitadine in combination with a fixed dose of lenalidominde and dexamethasone in patients with relapased/refractory multiple myeloma. This study is for patients who have previously been diagnosed with multiple myeloma and who have previously been treated unsuccessfully with lenalidomide.
The dose levels of oral azacitadine are:
1 (A) 100mg for days 1-14 of 28 day cycle
2 (B) 100mg for days 1-21 of 28 day cycle
3 (C) 150mg for days 1-14 of 28 day cycle
4 (D) 150mg for days 1-21 of 28 day cycle
5 (E) 200mg for days 1-14 of 28 day cycle
6 (F) 200mg for days 1-21 of 28 day cycle
The fixed dose of lenalidomide is 25mg on Day 1 to 21 of each 28-day cycle.
The fixed dose of dexamethasone is 40mg on Day 1, 8, 15 and 22 or each 28-day cycle.
A total of up to 30 patients may take part in this trial. The first 3 patients will be enrolled in the lowest dose level 1(A). If this dose level is tolerated well by these patients, the next 3 patients will be enrolled in the next dose level 2(B), and so on until a dose level is reached where too many side effects are experienced. The dose level below the one with too many side effects will be declared the Maximum Tolerated Dose (MTD) and patients will drop back to this dose level and continue at this dose. This MTD dose level will be expanded to allow up to 22 patients to receive this dose.
You may be eligible to join this study is you are above 18 years of age and have adequate liver, kidney and bone marrow function; have no contrainidications to the use of azacitidine, lenalidomide or dexamethasone; you provide consent; you have not had therapy for your multiple myeloma in the last 4 weeks and agree to practise abstinence or use contraception for the specified time period.